In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...

Prostate cancer screenings slash the risk of dying from the disease in the following decades, according to new research. The screening measures the amount of prostate-specific antigen (PSA) in men’s ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

Screening men for prostate cancer would save thousands of lives by slashing their risk of dying from the disease by 13 per cent, a major study reveals. Testing led to a ‘sustained reduction’ in deaths ...

Living with prostate cancer can be very stressful. It can affect a person’s body, life plans, relationships, and emotions. Many people don’t realize that people with prostate cancer are at risk for ...

Those with prostate cancer that returns after surgery or radiation—and typically face a high risk of the disease spreading and death—could benefit from a new drug combination. A Cedars-Sinai Medical ...